Tomas Pika

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Introduction:Achievement of minimal residual disease negativity (MRD‚Äì) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival. ...

Nelson Castro ;

Tomas Pika ;

Javier De la Rubia ;

Angelo Maiolino ;

Anthony Reiman ;

Thomas G. Martin III, MD;

Sylvia Marion ;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sosana Delimpasi ;

Joaquin Martinez-Lopez ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Meletios-Athanasios Dimopoulos ;

France Casca ;

Marie-Laure Risse ;

Bradle Augustson ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Tomas Pika

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products